Elicio posts Q2 net loss $7.6M, cash $21.7M; reports interim AMPLIFY-201 data

Elicio Therapeutics, Inc.

2023-Q2 EPS reported -$9.06

Net loss $7.6M ($2.61/share) vs $7.3M; cash $21.7M at June 30 vs $6.2M at Dec 31, 2022.
R&D expense $4.9M, G&A $2.8M (up vs $1.2M) due to reverse merger and public company costs.
AMPLIFY-201 interim data: ELI-002 induced mKRAS T-cell response (56-fold avg); tumor biomarker reduced in 77% of patients.
AMPLIFY-7P Phase 1A enrollment initiated for ELI-002 7P; Phase 1B RP2D initiation expected Q3 2023.
Completed reverse merger in Q2 2023; common stock now trading on Nasdaq.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Elicio Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss for the second quarter of 2023 was $7.6 million, EPS Net loss per share for the second quarter of 2023 was $2.61.

Period: the second quarter ended June 30, 2023
Net income: Net loss for the second quarter of 2023 was $7.6 million
EPS: Net loss per share for the second quarter of 2023 was $2.61
Result: reported results

Exact text from the filing

Elicio Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended June 30, 2023.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Elicio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001601485-23-000048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.